Anniccherico Sánchez, Francisco Javier
Loading...
Email Address
person.page.identifierURI
Birth Date
Job Title
Last Name
Anniccherico Sánchez
First Name
Francisco Javier
person.page.departamento
Ciencias de la Salud
person.page.instituteName
ORCID
person.page.observainves
person.page.upna
Name
- Publications
- item.page.relationships.isAdvisorOfPublication
- item.page.relationships.isAdvisorTFEOfPublication
- item.page.relationships.isAuthorMDOfPublication
2 results
Search Results
Now showing 1 - 2 of 2
Publication Open Access Factores asociados a la recurrencia y supervivencia en el Tromboembolismo pulmonar(2020) Anniccherico Sánchez, Francisco Javier; Casas Fernández de Tejerina, Juan Manuel; Alonso Martínez, José Luis; Ciencias de la Salud; Osasun ZientziakBackground: Venous thromboemboli tend to recur. However, the causative factors underlying pulmonary embolism recurrence are not well defined. Aims: To explore the factors associated with pulmonary embolism recurrence. Patients and methods: Patients diagnosed with pulmonary emboli between 2004 and 2013 at our institution were enrolled. Duration of anticoagulant therapy, new episodes of venous thromboembolism, and deaths were recorded. Results: Pulmonary embolism was diagnosed in 528 patients (median age: 76 years, interquartile range [IQR]: 16; male: 45%). The median follow-up time was 34 months (IQR: 52). In total, 477 patients completed ≥3 months of anticoagulation therapy. Permanent anticoagulation was indicated in 217 (45%) patients, and therapy was discontinued in 260 (55%) patients. Overall, 79 patients experienced a recurrence (5.6 per patient-year). Recurrence was significantly associated with anticoagulation discontinuation (4% vs. 27% of patients who maintained or discontinued therapy, respectively; P<0.001; 95% confidence interval -0.95, -0.86). The median duration between anticoagulation withdrawal and recurrence was 6.5 months (IQR: 23.25). Factors associated with recurrence were unprovoked pulmonary embolism (odds ratio [OR]: 0.45), a greater degree of pulmonary arterial obstruction (OR: 2.5), a delay in initiation of anticoagulation (OR: 3), and higher plasma D-dimer levels during treatment (OR: 2.3). Survival rates were improved for patients who maintained anticoagulation therapy relative to those who discontinued. Conclusion: Pulmonary embolism has a high recurrence rate. Permanent anticoagulant therapy should be considered for patients with idiopathic pulmonary embolism, a high thrombotic burden, and persistently elevated D-dimer levels during treatment, and for patients where therapy was initially delayed.Publication Open Access Lesiones esplénicas en medicina interna(Gobierno de Navarra. Departamento de Salud, 2014) Rojo Álvaro, Jorge; Anniccherico Sánchez, Francisco Javier; Alonso Martínez, José Luis; Pérez Ricarte, S.; Oteiza Olaso, Julio; Casas Fernández de Tejerina, Juan Manuel; Ciencias de la Salud; Osasun ZientziakEl bazo representa el mayor órgano linfopoyético, contiene el 25% de la masa linfoide total. Participa en la inmunidad celular y humoral e interviene en la renovación de los glóbulos rojos y en la eliminación de las bacterias. Las funciones esplénicas están reducidas cuando el bazo está ausente, lo que implica entre otras complicaciones, una mayor susceptibilidad para padecer una sepsis por organismos encapsulados. Se presentan 6 casos clínicos ingresados en el servicio de Medicina Interna con patología esplénica y se hace una revisión del abordaje a realizar. El espectro de lesiones esplénicas en medicina interna es muy amplio. En ocasiones se puede sospechar patología esplénica por la historia clínica, la exploración física o por citopenias en los análisis. Disponemos de diversas pruebas complementarias para completar el estudio de dichas lesiones. En caso de duda diagnóstica se puede realizar esplenectomía siendo los diagnósticos más frecuentes la cirrosis hepática y el linfoma/leucemia.